





THE NEW DIMENSION IN CARDIOVASCULAR DIAGNOSIS AND MONITORING

OPTIMISED FOR FLUID MANAGEMENT



APPLICATIONS

MONITORING AND FLUID MANAGEMENT

Intensive Care Unit Emergency Department Heart Failure Anaesthesiology Intermediate Care Paediatrics

- · establish baseline hemodynamics
- · evaluate and manage the fluid level of a patient
- trend and detect hemodynamic changes for timely intervention
- monitor drug titration to evaluate and optimise treatment
- \cdot early identification of the development of oedema by measuring TFC
- · possible reduction of catheter use or when the catheter is withdrawn
 - \cdot when a catheter is too risky, invasive or costly

"... bioimpedance cardiography has been shown to be accurate and clinically interchangeable with the existing technology of Pulmonary Artery Catheterization." *1 "Measurements are highly reproducible on same-day determinations and show device sensitivity to normal hemodynamic changes on inter-day measurements. The availability of expected hemodynamic ranges provides a baseline for objective determination of responses to therapeutic interventions." *2

HYPERTENSION MANAGEMENT

Hypertension Clinics Physician' s Office

- \cdot determine cause of high blood pressure in order to target, optimise, and validate medications
- define most effective antihypertensive drug combination (Beta-blocker, ACE inhibitor, Diuretic and others)
 balance systemic vascular resistance, cardiac output and fluid level (TFC)
- measure aortic pulse wave velocity to evaluate arterial stiffness as an independent predictor of cardiovascular risk and to monitor drugs that can improve it

"... non-invasive hemodynamic management achieved superior BP levels and control rates, when compared to management by experienced hypertension clinicians. Our results suggest that sequential non-invasive hemodynamics provide effective guidance in drug selection and titration in treatment of resistant hypertensives." *3

CARDIOVASCULAR DIAGNOSIS

Rehabilitation Physician' s Office

- evaluate heart performance by different function tests (orthostatic test, Valsalva manoeuvre)
- · measure aortic pulse wave velocity to evaluate arterial stiffness for cardiovascular risk stratification
- · combine with the measurement of Ankle-Brachial-Index (ABI) to analyse arteriosclerotic changes using the VasoScreen device

"Because arterial stiffness is an independent predictor of cardiovascular risk, there is now great interest in its use for cardiovascular risk stratification and to monitor drugs that can alter / improve aortic stiffness." *5

PACEMAKER ADJUSTMENT

Electrophysiology Physician' s Office • optimise AV-delay and VV-delay in multi-chamber pacemakers • resynchronisation therapy (CRT)

"In patients undergoing ventricular resynchronisation therapy, AV delay optimization based on CO determination by impedance cardiography is comparable to that measured by transmitral flow pulsed Doppler. However, ICG seems a more objective and simpler technique." *6

PHARMACEUTICAL CLINICAL TRIALS

Phase I – III Studies

• facilitate early decision making in drug development and clinical trials

2007 Guidelines for the Management of Arterial Hypertension. $\,^{\star}4$


METHODS

IMPEDANCE CARDIOGRAPHY (ICG)

Changes in volume and velocity of blood in the aorta cause variations in the thoracic bio-impedance which is measured and displayed as the ICG waveform. This signal is applied to innovative algorithms to provide key hemodynamic parameters non-invasively and continuously. The accuracy of the method is further improved by the arterial compliance modulation technology (ACM) for which a special ear clip has to be placed.

AORTIC PULSE WAVE VELOCITY (PWVao)

The opening of the aortic valve, when the blood is pumped into the aorta, is defined as the B-point in the ICG signal. On the upper leg a pressure cuff is placed to measure the arrival of the Pulse Wave (PW) and to define its Propagation Time (PT). Taking into consideration the distance between aortic valve and pressure cuff the aortic Pulse Wave Velocity (PWVao) can be calculated to evaluate arterial stiffness for cardiovascular risk stratification.



PARAMETERS

FLOW

HR	Heart Rate	Heart beats per minute
BP	Blood Pressure	Pressure exerted by the blood on arterial walls
SV SI	Stroke Volume Stroke Index	Amount of blood pumped by the left ventricle with each heart beat
CO CI	Cardiac Output Cardiac Index	Amount of blood pumped by the heart in one minute

CONTRACTILITY

VI	Velocity Index	Reflects the peak velocity of blood flow in the aorta during systole
ACI	Acceleration Index	Reflects the maximum acceleration of blood flow in the aorta during systole
HI	Heather Index	Contractility indicator
PEP	Pre-Ejection Period	Duration of electrical systole equal to isovolu- metric contraction phase
STR	Systolic Time Ratio	Ratio of electrical systole to mechanical systole

FLUID


TFC	Thoracic Fluid Content	Indicator of chest fluid status
TFCI	TFC Index	TFC, normalised to body size

VASCULAR

РТ	Propagation Time	Propagation time of the pulse wave
PWVac	Pulse Wave Velocity	Velocity of the aortic pulse wave
SVR SVRI	Systemic Vascular Resistance SVR Index	The force the ventricle must overcome to eject blood into the aorta, estimate of "afterload" SVR, normalised to body size
tac taci	Total Arterial Compliance TAC Index	Indicator of the degree of peripheral arterial stiffness / compliance TAC, normalised to body size

SIGNAL QUALITY

Signal Quality Indicator for validation of ICG waveforms shows the quality of the beats used for calculations. Key events of the cardiac cycle are indicated by markers: aortic valve opens (B), peak systolic flow (C) and aortic valve closes (X).



SCREENS

MONITORING




FLUID MANAGEMENT

 Passive Leg Raising (PLR) test
 standardised procedure
 automatic evaluation

DIAGNOSTIC

- · 7 selectable parameter
- bars with
- reference ranges
- · ICG and ECG waveforms



TRENDS

- 4 selectable parameters
- · Selectable time scaling
- Event markers
- \cdot ICG and ECG waveforms

ECG	h	_h_	M_	L_	h_	M	-lp	~~~~
ICG	Λ	Λ	Λ	Λ	Λ	Λ	~/\	~~~~
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	~~~~~	~~~	- m-	~~~	~~	Quality Indicator IC	G 100%
HR 17min	• ⁸⁶⁻ 63 58-	~~~	~~~~	~				
MAP mmHg	105- <b>106</b> 70-			_				
SV ml	135- 109 72-		~~~~	~				
CI Umin/m ¹	4.7- <b>3.3</b> 2.5-	01-04-0 11:06:0		11:10:00	11:12:00	11:14:00	11:16:00	11:18:00

11:09:14

## THERAPEUTIC

- 6 selectable parameters
- Therapeutic graph and
- TFC scale · ICG and ECG waveforms



## **PRODUCTS** Non-Invasive · Continuous · Easy

NICCOMO®

Non-Invasive Continuous Cardiac Output Monitor





• Continuous (beat-to-beat) monitoring and recording of curves and 29 parameters • Continuous signal quality control and adaptive artefact elimination

· Additional modules: NiBP · SpO2 · PWV (aortic Pulse Wave Velocity)

• 10" TFT colour display with touch screen • Battery available (capacity > 60 min)

#### **NEW STANDARDS**

## INNOVATIVE

Combination of hemodynamic parameters (ICG) and vascular stiffness (PWVao) to evaluate the complete cardiovascular system.

## Simple · Quick · Real-Time

#### CardioScreen 2000®

The optimal configuration for cardiovascular diagnosis

#### CardioScreen 1000®




www.cardioscreen.de



· Display of user selectable waveforms and parameters

- · Different screens for optimal data presentation in different clinical settings
- · Interface to patient monitors, such as Philips/HP (VueLink)



· Power supply via USB port

• External computer: Panel PC with touch screen, PC or Notebook • Combination with VasoScreen and TensoScreen devices possible

#### FLEXIBLE

Configurable measuring channels and user selectable parameters and screens. Interface to Philips / HP monitoring systems by supporting the VueLink protocol. Different device configurations depending on the needs of the customer.

## EASY TO USE

Highly sensitive measuring technology and intuitive operation by touch screen. USB interface for easy data backup and software updates.

# **TECHNICAL DATA**

Measurement Principle		Impedance Cardiography (ICG) Bio-impedance	Impedance Cardiography (ICG) Bio-impedance	Impedance Cardiography (ICG) Bio-impedance
Measurement Channels	Standard Configurable	ICG / ECG + ACM ECG · NIBP · SpO2 · PWVao	ICG / ECG + ACM ECG · NIBP · SpO2 · PWVao	ICG / ECG + ACM
Impedance Cardiography (ICG)	Meas. current Basic impedance Imp. change Safety	1.5 mA eff, 85 kHz 0-60 Ohm, 0-1.5 Hz $\pm$ 1 Ohm, 0.2-160 Hz defibrillator protected	1.5 mA eff, 85 kHz 0–60 Ohm, 0–1.5 Hz ± 1 Ohm, 0.2–160 Hz defibrillator protected	1.5 mA eff, 85 kHz 0–60 Ohm, 0–1.5 Hz ± 1 Ohm, 0.2–160 Hz defibrillator protected
ECG	Input voltage Safety	$\pm$ 10 mV AC, 0.2–160 Hz defibrillator protected	$\pm$ 10 mV AC, 0.2–160 Hz defibrillator protected	± 10 mV AC, 0.2–160 Hz defibrillator protected
Pulse Wave (PW)	Meas. method Frequency range Cuff pressure	Air plethysmography 0.2–30 Hz 60 mmHg	Air plethysmography 0.2–30 Hz 60 mmHg	
NIBP	Measuring range Accuracy	40-260 mmHg ± 3 mmHg	40-260 mmHg ± 3 mmHg	
SpO2	Measuring range Accuracy	1-100 % SpO2 ± 2 % (at 70 %-100 % SpO2)	1-100 % SpO2 ± 2 % (at 70 %-100 % SpO2)	
Power Supply		100–240 V AC, 50 / 60 Hz max. 60 VA Battery: NiMH, cap. > 60 min	100–240 V AC, 50 / 60 Hz max. 40 VA	via USB port
Dimensions	$w \times h \times d$	290 × 320 × 140 mm	310 × 260 × 90 mm	75 × 25 × 130 mm
Weight		Approx. 5 kg (including battery)	Approx. 2 kg	Approx. 300 g
Display		10.4 " TFT color with touch screen	External computer	External computer
Safety	Medical Device Directive Standards	Class II a IEC / EN 601-1 (Class I, Type BF) IEC / EN 601-1-2 CE 0197	Class II a IEC / EN 601-1 (Class I, Type BF) IEC / EN 601-1-2 CE 0197	Class II a IEC / EN 601-1 (Class I, Type BF) IEC / EN 601-1-2 CE 0197
PC Requirements			Medical PC necessary Operat. system: Windows / Linux RAM: > 512 MB HD: > 40 GB Interface: USB port	Medical PC necessary Operat. system: Windows / Linux RAM: > 512 MB HD: > 40 GB Interface: USB port

**NICCOMO®** 

*1 | Sageman W, Riffenburgh H, Spiess BD. Equivalence of bioimpedance and thermodilution in measuring cardiac index after cardiac surgery. J Cardiothorac Vasc Anesth. 2002; 16: 8-14

- *2 | Verhoeve PE, Cadwell CA, Tsadok S. Reproducibility of non-invasive bioimpedance measurements of cardiac function. J Cardiac Fail. 1998; 4 (3 Suppl): 53 *3 | Taler SJ, Textor SC, Augustine JE. Resistant Hypertension: Comparing hemodynamic management to specialist care. Hypertension. 2002; 39: 982-988

*4 The Task Force for the Management of Arterial Hypertension of European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2007; 25: 1105-1187

*5 | Asmar R. Arterial stiffness and pulse wave velocity: Clinical applications, Elsevier, 1999

*6 | Santos JF, Parreira L, Madeira J, Fonseca N, Soares LN, Ines L. Rev Port Cardiol. 2003; 22 (9): 1091-1098

## AUTHORISED DISTRIBUTOR

#### medis · Medizinische Messtechnik GmbH

Werner-von-Siemens-Str. 8 · 98693 Ilmenau · Germany phone + 49 (0)3677 46290 · fax + 49 (0)3677 462929 info@medis-de.com · www.medis-de.com

### CardioScreen 1000®

CardioScreen 2000®

V 2.0